Mass Cytometry Immunophenotyping of Graft-Conditioned Cells Following Major Histocompatibility Complex Mismatched Murine Allograft
- 19 March 2025
- book chapter
- Published by Springer Nature
- Vol. 2907, 259-286
Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for a variety of blood disorders but primarily reserved for blood cancer patients due to the life-threatening risk of acute graft-versus-host disease (aGVHD). Development of aGVHD is driven by alloreactive T cells that recognize the recipient's tissues as foreign and initiate a robust immune response causing severe tissue damage of the skin, liver, and gut. While methods to reduce aGVHD incidence and severity exist including posttransplant cyclophosphamide, relapse rates and transplantation-related mortality remain. We previously published a study using graft conditioning with glucocorticoids as a strategy to modify the immune repertoire in the donor grafts prior to transplantation to reduce aGVHD. Here, we describe a protocol to characterize the T-cell response in recipient mice given transplantation of graft-conditioned allogeneic donor cells via mass cytometry. Mass cytometry is a technology that uses heavy metal tags in place of fluorochromes to allow high-dimensional flow cytometric analysis. In this protocol, we include an antibody panel of 39 different antibodies conjugated to 41 different heavy metal tags that have been validated and titrated for barcoding and immunophenotyping by lineage markers, activation markers, cytokine secretion, and transcription factors. This chapter details the graft conditioning, transplantation, processing, barcoding, staining, and mass cytometric analysis of immune cells following murine allo-HCT.Keywords
This publication has 18 references indexed in Scilit:
- Do more with Less: Improving High Parameter Cytometry Through Overnight StainingCurrent Protocols, 2022
- Current Concepts and Advances in Graft-Versus-Host Disease ImmunologyAnnual Review of Immunology, 2021
- Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin InhibitorsTransplantation and Cellular Therapy, 2020
- Immune monitoring using mass cytometry and related high-dimensional imaging approachesNature Reviews Rheumatology, 2019
- Natural Killer Cells in GvHD and GvL2019
- Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern YearsTransplantation and Cellular Therapy, 2016
- FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry dataCytometry Part A, 2015
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008
- CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantationNature Medicine, 2003
- The graft-versus-leukemia effectCurrent Opinion in Hematology, 1996